CoChat
Sign Up
Cited by 86Treatment of Major DepressionNeurotransmitter Receptor Influence on BehaviorTryptophan and brain disorders

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant

Open access
Sowa-Kućma, Magdalena, Pańczyszyn-Trzewik, Patrycja, Misztak, Paulina, Jaeschke, Rafał R., Sendek, Katherine, Styczeń, Krzysztof, Datka, Wojciech, Koperny, Magdalena·2017·Pharmacological Reports
DOI 10.1016/j.pharep.2017.01.030
Open this paper in CoChat — free account

Abstract

The aim of this paper was to review the up-to-date evidence base on pharmacology and clinical properties of vortioxetine. Vortioxetine is a novel antidepressant, approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD). Because vortioxetine exhibits both an antidepressant and anxiolytic effect, it may be effective in treating both depressive and anxiety disorders, such as generalized anxiety disorder (GAD). Based on its pharmacodynamics profile and preclinical studies, it is believe that the drug's clinical action is mediated mainly by selective blockade of serotonin reuptake (by inhibiting the serotonin transporter [SERT]) and direct modulation of 5-HT receptors activity (such as 5-HT 3 , 5-HT 7 , 5-HT 1D and 5-HT 1B ). In patients with MDD the recommended doses range is 5-20mg/day. Vortioxetine was shown to be more effective than placebo both in MDD and GAD. In terms of side effects, nausea, vomiting, diarrhea, and dry mouth were most commonly observed in individuals receiving vortioxetine. In direct comparison to duloxetine, vortioxetine is found to have a smaller efficacy but had a lower risk of developing the common antidepressant-induced adverse effects.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pharep.2017.01.030

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Vortioxetine's clinical action is mediated mainly by selective blockade of serotonin reuptake and direct modulation of serotonergic receptor activity, including 5-HT3, 5-HT7, 5-HT1D, and 5-HT1B.

    “Effects on sleep has recently been also reported for a vortioxetine, with clinical action mediated mainly by selective blockade of serotonin reuptake and direct modulation of serotonergic receptors activity (such as 5-HT3, 5-HT7, 5-HT1D, and 5-HT1B) [27].”

    From Effects of Antidepressants on Sleep (2017) · cites this paper as [27]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 47

  1. Lorenzo-Luaces, 2015, Heterogeneity in the prognosis of major depression: from the common cold to a highly debilitating and recurrent illness, Epidemiol Psychiatr Sci, 24, 466, 10.1017/S2045796015000542 · DOI · Paper page
  2. Kohler, 2016, The serotonergic system in the neurobiology of depression: relevance for novel antidepressants, J Psychopharmacol, 30, 13, 10.1177/0269881115609072 · DOI
  3. Lane, 2015, Antidepressant drug development: focus on triple monoamine reuptake inhibition, J Psychopharmacol, 29, 526, 10.1177/0269881114553252 · DOI
  4. D'Agostino, 2015, Vortioxetine (brintellix): a new serotonergic antidepressant, P T, 40, 36
  5. Garnock-Jones, 2014, Vortioxetine a review of its use in major depressive disorder, CNS Drugs, 28, 855, 10.1007/s40263-014-0195-x · DOI
  6. Richelson, 2003, Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance, J Clin Psychiatry, 64, 5
  7. Blier, 2003, Is there a role for 5-HT1A agonists in the treatment of depression, Biol Psychiatry, 53, 193, 10.1016/S0006-3223(02)01643-8 · DOI
  8. Celada, 2013, Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research, CNS Drugs, 27, 703, 10.1007/s40263-013-0071-0 · DOI · Paper page
  9. Bonaventure, 2007, Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents, J Pharmacol Exp Ther, 321, 690, 10.1124/jpet.107.119404 · DOI
  10. Costall, 2004, 5-HT3 receptors, Curr Drug Targets CNS Neurol Disord, 3, 27, 10.2174/1568007043482624 · DOI
  11. Ramamoorthy, 2008, Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models, Behav Pharm, 19, 29, 10.1097/FBP.0b013e3282f3cfd4 · DOI
  12. Brintellix (TM). IDdb author IDDB MEETING REPORT 2009 Medicinal Chemistry – Fourth Anglo-Swedish Symposium (Part I). Lund, Sweden.
  13. Areberg, 2012, The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers, Basic Clin Pharmacol Toxicol, 111, 198, 10.1111/j.1742-7843.2012.00886.x · DOI · Paper page
  14. Gibb, 2014, Vortioxetine first global approval, Drugs, 74, 135, 10.1007/s40265-013-0161-9 · DOI
  15. Areberg, 2012, Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects, Basic Clin Pharmacol Toxicol, 110, 401, 10.1111/j.1742-7843.2011.00810.x · DOI · Paper page
  16. Citrome, 2014, Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed, Int J Clin Pract, 68, 60, 10.1111/ijcp.12350 · DOI
  17. Chen, 2013, Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant, Clin Drug Investig, 33, 727, 10.1007/s40261-013-0117-6 · DOI
  18. Uldam, 2011, Biosynthesis and identification of an N-oxide/N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004, Drug Metab Dispos, 39, 2264, 10.1124/dmd.111.040428 · DOI
  19. Hvenegaard, 2012, Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004, Drug Metab Dispos, 40, 1357, 10.1124/dmd.112.044610 · DOI
  20. Baldwin, 2016, The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies, J Psychopharmacol, 30, 242, 10.1177/0269881116628440 · DOI
  21. Katona, 2014, New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder, Neuropsychiatr Dis Treat, 10, 349, 10.2147/NDT.S39544 · DOI
  22. Spina, 2015, Drug interactions with vortioxetine, a new multimodal antidepressant, Riv Psichiatr, 50, 210
  23. Pehrson, 2013, Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters–a rat microdialysis and electrophysiology study, Eur Neuropsychopharmacol, 23, 133, 10.1016/j.euroneuro.2012.04.006 · DOI · Paper page
  24. Betry, 2013, The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism, Int J Neuropsychopharmacol, 16, 1115, 10.1017/S1461145712001058 · DOI
  25. Dale, 2014, Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus, J Psychopharmacol, 28, 891, 10.1177/0269881114543719 · DOI · Paper page
  26. El Mansari, 2015, Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain, Psychopharmacology (Berl), 232, 2343, 10.1007/s00213-015-3870-9 · DOI
  27. Guilloux, 2013, Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice, Neuropharmacology, 73, 147, 10.1016/j.neuropharm.2013.05.014 · DOI
  28. Li, 2013, Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats, Behav Brain Res, 256, 520, 10.1016/j.bbr.2013.09.002 · DOI
  29. Overstreet, 2013, The flinders sensitive line rat model of depression–25 years and still producing, Pharmacol Rev, 65, 143, 10.1124/pr.111.005397 · DOI
  30. Westrich, 2015, Involvement of 5-HT(7) receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents, Neuropharmacology, 89, 382, 10.1016/j.neuropharm.2014.10.015 · DOI
  31. du Jardin, 2014, Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism, Eur Neuropsychopharmacol, 24, 160, 10.1016/j.euroneuro.2013.07.001 · DOI · Paper page
  32. Mork, 2013, Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats, Pharmacol Biochem Behav, 105, 41, 10.1016/j.pbb.2013.01.019 · DOI
  33. Wallace, 2014, Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats, Int J Neuropsychopharmacol, 17, 1695, 10.1017/S1461145714000571 · DOI · Paper page
  34. Goetghebeur, 2009, Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat-a back translational study, Psychopharmacology (Berl), 202, 287, 10.1007/s00213-008-1132-9 · DOI
  35. Theunissen, 2013, A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition, Clin Pharmacol Ther, 93, 493, 10.1038/clpt.2013.39 · DOI
  36. Berhan, 2014, Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials, BMC Psychiatry, 14, 276, 10.1186/s12888-014-0276-x · DOI
  37. Pae, 2015, Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder, J Psychiatry Neurosci, 40, 174, 10.1503/jpn.140120 · DOI
  38. Meeker, 2015, The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis, Syst Rev, 4, 21, 10.1186/s13643-015-0001-y · DOI
  39. Fu, 2015, The efficacy and safety of 5mg/d Vortioxetine compared to placebo for major depressive disorder: a meta-analysis, Psychopharmacology (Berl), 232, 7, 10.1007/s00213-014-3633-z · DOI
  40. Thase, 2016, A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults, Eur Neuropsychopharmacol, 26, 979, 10.1016/j.euroneuro.2016.03.007 · DOI
  41. Llorca, 2014, Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies, Curr Med Res Opin, 30, 2589, 10.1185/03007995.2014.969566 · DOI
  42. Li, 2016, Vortioxetine versus duloxetine in the treatment of patients with major depressive disorder: a meta-analysis of randomized controlled trials, Clin Drug Investig, 36, 509, 10.1007/s40261-016-0396-9 · DOI
  43. Wang, 2015, Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study, Curr Med Res Opin, 31, 785, 10.1185/03007995.2015.1014028 · DOI
  44. Rothschild, 2012, Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States, Eur Neuropsychopharmacol, 22, 858, 10.1016/j.euroneuro.2012.07.011 · DOI
  45. Pae, 2015, Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis, J Psychiatr Res, 64, 88, 10.1016/j.jpsychires.2015.02.017 · DOI
  46. Citrome, 2016, Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed, J Affect Disord, 196, 225, 10.1016/j.jad.2016.02.042 · DOI
  47. Fu, 2016, The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis, Neuropsychiatr Dis Treat, 12, 951, 10.2147/NDT.S104050 · DOI

Cited by

Sorted by citations

Metadata

Authors
Sowa-Kućma, M., Pańczyszyn-Trzewik, P., Misztak, P., Jaeschke, R. R., Sendek, K., Styczeń, K., Datka, W., & Koperny, M.
Affiliations
  • Maj Institute of Pharmacology (PL)
  • Jagiellonian University (PL)
Corresponding author
Sowa-Kućma, Magdalena
ORCID
Venue
Pharmacological Reports
Publisher
Springer Science and Business Media LLC
Published
2017-08
Volume
69
Issue
4
Pages
595-601
ISSN
1734-1140 (ISSN-L)
DOI
10.1016/j.pharep.2017.01.030
OpenAlex
W2585390649
Cited by
86
References
9
Citations by year
2026: 12 · 2025: 13 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 12 · 2020: 12 · 2019: 10 · 2018: 4 · 2017: 3
FWCI
0.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Pharmacological Reports (publishedVersion)
  • PubMed (publishedVersion)
  • Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
  • Jagiellonian University Repository (Jagiellonian University) (submittedVersion, other-oa)
  • BOA (University of Milano-Bicocca) (submittedVersion)
Funders
Uniwersytet Jagielloński Collegium Medicum
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
vortioxetine, antidepressants, major depressive disorder, generalized anxiety disorder, serotonin reuptake inhibition, serotonin transporter, pharmacodynamics, pharmacokinetics, adverse effects
MeSH terms
Vortioxetine, Animals, Antidepressive Agents, Depressive Disorder, Humans, Piperazines, Sulfides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review